ATE415941T1 - Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren - Google Patents

Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren

Info

Publication number
ATE415941T1
ATE415941T1 AT96909604T AT96909604T ATE415941T1 AT E415941 T1 ATE415941 T1 AT E415941T1 AT 96909604 T AT96909604 T AT 96909604T AT 96909604 T AT96909604 T AT 96909604T AT E415941 T1 ATE415941 T1 AT E415941T1
Authority
AT
Austria
Prior art keywords
pct
controlled release
medicinal products
soluble receptors
ligand
Prior art date
Application number
AT96909604T
Other languages
English (en)
Inventor
David Wallach
Josef Kost
Rom Eliaz
Original Assignee
Yeda Res & Dev
Univ Ben Gurion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Univ Ben Gurion filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE415941T1 publication Critical patent/ATE415941T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96909604T 1995-03-01 1996-03-01 Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren ATE415941T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11283495A IL112834A (en) 1995-03-01 1995-03-01 Pharmaceutical compositions for controlled release of soluble receptors

Publications (1)

Publication Number Publication Date
ATE415941T1 true ATE415941T1 (de) 2008-12-15

Family

ID=11067150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96909604T ATE415941T1 (de) 1995-03-01 1996-03-01 Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren

Country Status (19)

Country Link
US (1) US6083534A (de)
EP (1) EP0812208B1 (de)
JP (1) JP4447052B2 (de)
KR (1) KR100417650B1 (de)
CN (1) CN1133464C (de)
AT (1) ATE415941T1 (de)
AU (1) AU692384B2 (de)
BR (1) BR9607289A (de)
CA (1) CA2213560C (de)
DE (1) DE69637768D1 (de)
DK (1) DK0812208T3 (de)
EA (1) EA199700206A1 (de)
ES (1) ES2318849T3 (de)
IL (1) IL112834A (de)
MX (1) MX9706626A (de)
NO (2) NO323003B1 (de)
PT (1) PT812208E (de)
UA (1) UA44761C2 (de)
WO (1) WO1996026738A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
AU1345000A (en) * 1998-11-05 2000-05-22 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
AU3885901A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US8632845B2 (en) * 2000-12-28 2014-01-21 Abbott Cardiovascular Systems Inc. Method of drying bioabsorbable coating over stents
SI1471974T1 (sl) * 2002-02-06 2007-12-31 Ares Trading Sa Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih
HUE039377T2 (hu) * 2002-05-31 2018-12-28 L Molteni & C Dei Fratelli Alitti Soc Di Esercizio S P A Beültethetõ polimer eszköz buprenorfin folytonos kibocsátására
KR101101261B1 (ko) * 2002-07-19 2012-01-04 인스티튜트 오브 머티어리얼스 리서치 & 엔지니어링 생체분해성 삼블럭 공중합체, 이의 합성 방법, 및이로부터 제조된 하이드로겔 및 생체물질
MXPA05010450A (es) 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
US20060046960A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
JP5294635B2 (ja) * 2004-11-29 2013-09-18 イエダ リサーチ アンド デベロップメント カンパニー リミテッド コポリマー１と組み合わせた、神経発生の誘発及び幹細胞治療
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
KR101446503B1 (ko) * 2005-06-24 2014-10-06 듀크 유니버시티 열 반응성 생중합체에 기초한 직접 약물 전달 시스템
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
US20090183503A1 (en) * 2008-01-18 2009-07-23 Alberto Verdesi Exhaust apparatus
KR20190026056A (ko) 2008-04-21 2019-03-12 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
CA2731769C (en) 2008-07-21 2013-09-10 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
EA029956B1 (ru) 2011-03-25 2018-06-29 Эмджен Инк. Кристаллы антител против склеростина и составы на их основе
US20150125471A1 (en) * 2012-05-03 2015-05-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
WO2014046631A1 (en) 2012-09-19 2014-03-27 Tezcaner Aysen CONTROLED DRUG DELIVERY SYSTEMS FOR ANTI-TNF-α
CN105142688B (zh) 2014-02-04 2018-01-19 艾博特心血管***公司 具有基于novolimus和丙交酯的涂层使得novolimus与涂层具有最小键合量的药物递送支架或支撑件
WO2016010927A1 (en) 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
MX2017000526A (es) 2014-07-14 2017-08-02 Amgen Inc Formulaciones de anticuerpos cristalinos.
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
EP3328898B8 (de) 2015-07-28 2024-04-10 6452728 Canada Corp. Trkb- oder trkc-agonisten-zusammensetzungen und verfahren zur behandlung von erkrankungen des ohrs
JP5938762B1 (ja) 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
USD802757S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
JP2021524841A (ja) 2018-05-24 2021-09-16 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
CN111989068A (zh) 2018-05-24 2020-11-24 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
SE8804164A0 (sv) * 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5478564A (en) * 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0646000A4 (de) * 1992-11-16 1997-05-02 Univ Mercer Zusammensetzungen, die mikroverkapselte neutralisierende antikörper enthalten.

Also Published As

Publication number Publication date
CA2213560A1 (en) 1996-09-06
DE69637768D1 (de) 2009-01-15
CN1133464C (zh) 2004-01-07
EP0812208B1 (de) 2008-12-03
NO973812D0 (no) 1997-08-19
EP0812208A1 (de) 1997-12-17
CN1182369A (zh) 1998-05-20
MX9706626A (es) 1998-02-28
DK0812208T3 (da) 2009-03-16
IL112834A0 (en) 1995-06-29
EA199700206A1 (ru) 1998-02-26
NO973812L (no) 1997-11-03
ES2318849T3 (es) 2009-05-01
PT812208E (pt) 2009-02-06
IL112834A (en) 2000-12-06
UA44761C2 (uk) 2002-03-15
EP0812208A4 (de) 2004-06-30
NO20056197L (no) 1997-11-03
JP4447052B2 (ja) 2010-04-07
US6083534A (en) 2000-07-04
NO328034B1 (no) 2009-11-16
JPH11501306A (ja) 1999-02-02
KR100417650B1 (ko) 2004-05-20
AU5303996A (en) 1996-09-18
KR19980702640A (ko) 1998-08-05
BR9607289A (pt) 1998-06-23
AU692384B2 (en) 1998-06-04
WO1996026738A1 (en) 1996-09-06
CA2213560C (en) 2010-08-24
NO323003B1 (no) 2006-12-18

Similar Documents

Publication Publication Date Title
ATE415941T1 (de) Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren
GB2246295B (en) Continuous release pharmaceutical compositions
IS4187A (is) Ný lyfjablanda til inntöku um munn sem inniheldurnýtt magnesíumsalt ómeprasóls, aðferð við framleiðslu hennar og notkun
NZ291417A (en) Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
DE69228997T2 (de) Menschliche il-3-varianten
DE69227259T2 (de) Film zur lokalen arzneistoffabgabe für periodontale behandlung
DE69634080D1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel
GEP20032906B (en) Controlled Release Peroral Pharmaceutical Composition of Levosimendan for Treatment of Congestive Heart Failure

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0812208

Country of ref document: EP